Friday, November 06, 2009

gp130, IL-6 and Expression and Neuropathic Pain

We wanted to post yet another publication referencing use of one of our Pain and Inflammation Research Antibodies. Here the researchers used our Mouse Monoclonal gp130/CD130 for Immunohistochemistry.

Manfred Andratsch, Norbert Mair, Cristina E. Constantin, Nadja Scherbakov, Camilla Benetti, Serena Quarta, Christian Vogl, Claudia A. Sailer, Nurcan Üceyler, Johannes Brockhaus, Rudolf Martini, Claudia Sommer, Hanns Ulrich Zeilhofer, Werner Müller, Rohini Kuner, John B. Davis, Stefan Rose-John, and Michaela Kress. A Key Role for gp130 Expressed on Peripheral Sensory Nerves in Pathological Pain. J. Neurosci., Oct 2009; 29: 13473 - 13483 ; doi:10.1523/JNEUROSCI.1822-09.2009

The results suggest that gp130 expressed in sensory nerves not only mediates chronic inflammatory pain, but also contributes significantly to complex interactions between immune cells, tumor cells, and nerves in the context of cancer-evoked pain. Moreover, we identify IL-6 activating gp130, Gab1/Gab2, PI3K, and PKC- and regulating TRPV1 as a key mechanism linking cytokine release to sensitization of pain-sensing nerves.

Related Links
Immune Response
Opioid Neuropeptides
Opioid Receptors
Neurotransmissiom Research Antibodies
GPCRs, Ligand Gated Ion Channels, Biogenic Amines and more
Purinergic Receptors
TRPV (Vanilloid); TRPM; TRPA and TRPCs
i-Fect Transfection Kit
gene silencing of DOR, NaV1.8 tetrodotoxin-resistant sodium channel, NTS2 and more in-vitro and in vivo
Primary Neurons and Astrocytes
Primary human, rat and mouse neurons and astrocytes by Category

No comments: